Gilead Sciences is buying Arcellx in a deal worth $7.8 billion, picking up its partner on a CAR-T therapy for multiple myeloma.
#stockmarket #breaking
Stock Market juice!
Gilead Sciences is buying Arcellx in a deal worth $7.8 billion, picking up its partner on a CAR-T therapy for multiple myeloma.
#stockmarket #breaking